Zimmer Biomet (NYSE:ZBH) Price Target Raised to $110.00

Key Points

• Stifel Nicolaus raised Zimmer Biomet’s price target to $110 from $105 and maintained a “buy” rating, implying 13.18% upside from the prior close. However, analysts overall assign the stock an average “hold” rating with a consensus target of $102.75.
• Zimmer Biomet exceeded quarterly expectations, reporting adjusted EPS of $2.07 versus $2.01 expected and revenue of $2.18 billion versus $2.13 billion expected. Revenue rose 4.8% year over year, and management provided 2026 adjusted EPS guidance of $8.47–$8.59.
• The stock traded at $97.19, while analysts’ views remained mixed: one Strong Buy, eight Buys, thirteen Holds and three Sells. Investors may also weigh pressure on adjusted margins and the modest increase in guidance relative to consensus.

Zimmer Biomet (NYSE:ZBH - Get Free Report) had its price objective hoisted by investment analysts at Stifel Nicolaus from $105.00 to $110.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a "buy" rating on the medical equipment provider's stock. Stifel Nicolaus' price objective would suggest a potential upside of 13.18% from the company's previous close.

A number of other research firms also recently issued reports on ZBH. Barclays dropped their price objective on shares of Zimmer Biomet from $100.00 to $94.00 and set an "underweight" rating for the company in a report on Wednesday, April 29th. Wall Street Zen upgraded Zimmer Biomet from a "hold" rating to a "buy" rating in a research report on Saturday, July 25th. Citizens Jmp decreased their price target on shares of Zimmer Biomet from $120.00 to $105.00 and set a "market outperform" rating on the stock in a research note on Wednesday, April 29th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Zimmer Biomet in a research note on Thursday. Finally, UBS Group reissued a "buy" rating on shares of Zimmer Biomet in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $102.75.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH traded down $0.97 on Thursday, hitting $97.19. The company's stock had a trading volume of 215,132 shares, compared to its average volume of 2,319,140. Zimmer Biomet has a 1 year low of $79.12 and a 1 year high of $108.29. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. The company has a market capitalization of $18.80 billion, a PE ratio of 25.24, a PEG ratio of 2.82 and a beta of 0.45. The company has a 50-day simple moving average of $89.61 and a 200 day simple moving average of $90.02.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The company had revenue of $2.18 billion for the quarter, compared to analysts' expectations of $2.13 billion. During the same period in the prior year, the business earned $2.07 earnings per share. Zimmer Biomet's revenue for the quarter was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Sell-side analysts forecast that Zimmer Biomet will post 8.48 EPS for the current fiscal year.

Insider Buying and Selling at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of the business's stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the transaction, the insider directly owned 27,251 shares of the company's stock, valued at approximately $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.28% of the company's stock.

Hedge Funds Weigh In On Zimmer Biomet

A number of institutional investors have recently bought and sold shares of ZBH. DV Equities LLC purchased a new position in Zimmer Biomet during the fourth quarter valued at $25,000. Monetary Solutions Ltd purchased a new position in shares of Zimmer Biomet during the fourth quarter valued at approximately $30,000. Gen Wealth Partners Inc bought a new stake in shares of Zimmer Biomet in the 4th quarter worth approximately $31,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Zimmer Biomet in the 4th quarter worth approximately $32,000. Finally, Elevation Wealth Partners LLC increased its position in Zimmer Biomet by 145.9% during the 2nd quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider's stock valued at $33,000 after buying an additional 229 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Key Headlines Impacting Zimmer Biomet

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Quarterly earnings and revenue beat estimates. Zimmer Biomet reported adjusted diluted EPS of $2.07, above the $2.01 analyst consensus, while sales of $2.177 billion exceeded expectations of approximately $2.13 billion. Revenue increased 4.8% year over year, or 4.0% on an organic constant-currency basis. Zimmer Biomet Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year guidance was raised. Management now expects 2026 adjusted EPS of $8.47 to $8.59 and revenue of about $8.6 billion, compared with analyst expectations of $8.48 EPS and $8.5 billion in revenue. The higher sales outlook supports investor confidence in the company’s growth trajectory. Zimmer Biomet raises guidance on Q2 beats
• Positive Sentiment: GAAP profitability improved. Diluted EPS rose 33.8% to $1.03, while adjusted EPS remained stable year over year at $2.07. The earnings beat and raised outlook were the primary catalysts behind the favorable market reaction. Zimmer Biomet Q2 Earnings and Revenues Beat Estimates
• Neutral Sentiment: The guidance increase was modest relative to consensus. The midpoint of the new EPS range is only slightly above current analyst estimates, suggesting investors may continue to focus on execution and the pace of organic growth. Zimmer Biomet Q2 2026 Earnings Call Transcript
• Negative Sentiment: Adjusted margins were under pressure. Despite the earnings beat, profitability faced headwinds, which could limit further upside if cost pressures persist. ZBH's Q2 Earnings Beat, 2026 View Raised

Zimmer Biomet Company Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source